These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation. Doshi N; Martin J; Tomlinson A Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of a selective marker-based quantification of polysorbate 20 in biopharmaceutical formulations using UPLC QDa detection. Evers DH; Schultz-Fademrecht T; Garidel P; Buske J J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1157():122287. PubMed ID: 33069954 [TBL] [Abstract][Full Text] [Related]
5. Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method. Honemann MN; Wendler J; Graf T; Bathke A; Bell CH J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():1-8. PubMed ID: 30951966 [TBL] [Abstract][Full Text] [Related]
6. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics. Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888 [TBL] [Abstract][Full Text] [Related]
7. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method. Zhang S; Riccardi C; Kamen D; Xiao H; Li N Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481 [TBL] [Abstract][Full Text] [Related]
8. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation. Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486 [TBL] [Abstract][Full Text] [Related]
9. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80. Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015 [TBL] [Abstract][Full Text] [Related]
10. Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions. Glücklich N; Carle S; Buske J; Mäder K; Garidel P Eur J Pharm Sci; 2021 Nov; 166():105980. PubMed ID: 34419573 [TBL] [Abstract][Full Text] [Related]
11. High throughput FAMS - A fatty acid mass spectrometry method for monitoring polysorbate hydrolysis in QC. Hoelterhoff S; Wendler J; Arackal L; Felkel B; Bell CH; Bathke A J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Apr; 1220():123614. PubMed ID: 36989769 [TBL] [Abstract][Full Text] [Related]
12. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism. Tomlinson A; Demeule B; Lin B; Yadav S Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339 [TBL] [Abstract][Full Text] [Related]
13. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability. Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability. Tomlinson A; Zarraga IE; Demeule B Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382 [TBL] [Abstract][Full Text] [Related]
15. Degradation Mechanisms of Polysorbate 20 Differentiated by Zhang L; Yadav S; Demeule B; Wang YJ; Mozziconacci O; Schӧneich C Pharm Res; 2017 Jan; 34(1):84-100. PubMed ID: 27738952 [TBL] [Abstract][Full Text] [Related]
16. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins. Aryal B; Lehtimaki M; Rao VA Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663 [TBL] [Abstract][Full Text] [Related]
17. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time. Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968 [TBL] [Abstract][Full Text] [Related]
18. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material. Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966 [TBL] [Abstract][Full Text] [Related]
19. Acidic and alkaline hydrolysis of polysorbates under aqueous conditions: Towards understanding polysorbate degradation in biopharmaceutical formulations. Dwivedi M; Buske J; Haemmerling F; Blech M; Garidel P Eur J Pharm Sci; 2020 Mar; 144():105211. PubMed ID: 31931121 [TBL] [Abstract][Full Text] [Related]
20. A fast and sensitive high-throughput assay to assess polysorbate-degrading hydrolytic activity in biopharmaceuticals. Gupta SK; Graf T; Edelmann FT; Seelmann H; Reintinger M; Hillringhaus L; Bergmann F; Wiedmann M; Falkenstein R; Wegele H; Yuk IH; Leiss M Eur J Pharm Biopharm; 2023 Jun; 187():120-129. PubMed ID: 37116764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]